Stacy Emily Croteau, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hemophilia A | 30 | 2024 | 359 | 10.050 |
Why?
|
Hemophilia B | 12 | 2024 | 84 | 4.230 |
Why?
|
Factor VIII | 16 | 2024 | 348 | 3.250 |
Why?
|
Factor IX | 8 | 2022 | 77 | 1.660 |
Why?
|
Hemangioendothelioma | 3 | 2016 | 111 | 1.350 |
Why?
|
Sarcoma, Kaposi | 3 | 2016 | 374 | 1.120 |
Why?
|
Blood Coagulation Factors | 5 | 2024 | 365 | 1.110 |
Why?
|
Hemostatics | 4 | 2024 | 242 | 1.110 |
Why?
|
von Willebrand Diseases | 3 | 2021 | 132 | 0.930 |
Why?
|
Dependovirus | 3 | 2022 | 711 | 0.790 |
Why?
|
Antibodies, Bispecific | 2 | 2024 | 191 | 0.780 |
Why?
|
Cell-Derived Microparticles | 1 | 2021 | 161 | 0.660 |
Why?
|
Half-Life | 6 | 2020 | 652 | 0.630 |
Why?
|
Blood Specimen Collection | 1 | 2019 | 238 | 0.610 |
Why?
|
Blood Coagulation | 3 | 2020 | 1149 | 0.590 |
Why?
|
Transduction, Genetic | 1 | 2020 | 896 | 0.590 |
Why?
|
Genetic Vectors | 3 | 2022 | 3380 | 0.570 |
Why?
|
von Willebrand Factor | 2 | 2021 | 672 | 0.570 |
Why?
|
Compassionate Use Trials | 1 | 2016 | 50 | 0.540 |
Why?
|
Factor VIIa | 1 | 2016 | 103 | 0.510 |
Why?
|
Workflow | 1 | 2020 | 850 | 0.500 |
Why?
|
Medical Records | 1 | 2020 | 1406 | 0.480 |
Why?
|
Hemoglobin M | 1 | 2013 | 3 | 0.450 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 1673 | 0.430 |
Why?
|
Pharmaceutical Services | 1 | 2014 | 141 | 0.430 |
Why?
|
Osteoma, Osteoid | 1 | 2013 | 90 | 0.410 |
Why?
|
Codon | 1 | 2013 | 602 | 0.380 |
Why?
|
Frameshift Mutation | 1 | 2013 | 388 | 0.380 |
Why?
|
Hemangioma | 1 | 2016 | 727 | 0.380 |
Why?
|
Blood Coagulation Disorders | 1 | 2014 | 349 | 0.380 |
Why?
|
Thrombosis | 5 | 2023 | 2929 | 0.370 |
Why?
|
Recombinant Proteins | 3 | 2020 | 6520 | 0.370 |
Why?
|
Health Care Costs | 2 | 2021 | 3245 | 0.370 |
Why?
|
beta-Thalassemia | 1 | 2013 | 235 | 0.370 |
Why?
|
Patient Participation | 1 | 2020 | 1436 | 0.360 |
Why?
|
Genes, Dominant | 1 | 2013 | 862 | 0.360 |
Why?
|
Self Care | 1 | 2015 | 794 | 0.350 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 7985 | 0.300 |
Why?
|
Catheterization, Central Venous | 2 | 2023 | 526 | 0.290 |
Why?
|
Tibia | 1 | 2013 | 1065 | 0.290 |
Why?
|
Internet | 1 | 2019 | 3082 | 0.290 |
Why?
|
Exons | 1 | 2013 | 2387 | 0.280 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3175 | 0.280 |
Why?
|
Hemorrhage | 6 | 2024 | 3400 | 0.270 |
Why?
|
Decision Making | 1 | 2020 | 3915 | 0.270 |
Why?
|
Child, Preschool | 15 | 2024 | 42062 | 0.270 |
Why?
|
Health Personnel | 1 | 2020 | 3312 | 0.260 |
Why?
|
Adolescent | 19 | 2024 | 87892 | 0.260 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2307 | 0.250 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 3992 | 0.240 |
Why?
|
Child | 20 | 2024 | 79818 | 0.240 |
Why?
|
Venous Thromboembolism | 3 | 2023 | 1855 | 0.240 |
Why?
|
Humans | 50 | 2024 | 758406 | 0.220 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1402 | 0.210 |
Why?
|
Exercise | 1 | 2020 | 5788 | 0.210 |
Why?
|
Hemostasis | 3 | 2023 | 466 | 0.210 |
Why?
|
Lymph Nodes | 1 | 2013 | 3485 | 0.200 |
Why?
|
Endothelial Cells | 3 | 2022 | 3533 | 0.200 |
Why?
|
von Willebrand Disease, Type 3 | 1 | 2021 | 5 | 0.200 |
Why?
|
Physicians | 1 | 2019 | 4580 | 0.190 |
Why?
|
Bone Neoplasms | 1 | 2013 | 2531 | 0.180 |
Why?
|
Young Adult | 13 | 2024 | 58808 | 0.170 |
Why?
|
Congenital Disorders of Glycosylation | 1 | 2020 | 48 | 0.170 |
Why?
|
Infant | 10 | 2024 | 36055 | 0.170 |
Why?
|
Phosphatidylserines | 1 | 2021 | 188 | 0.170 |
Why?
|
Infusions, Intravenous | 2 | 2021 | 2210 | 0.160 |
Why?
|
Glycocalyx | 1 | 2020 | 94 | 0.160 |
Why?
|
Bioengineering | 1 | 2019 | 96 | 0.160 |
Why?
|
Neuropsychology | 1 | 2019 | 107 | 0.160 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11152 | 0.160 |
Why?
|
Adult | 16 | 2022 | 219935 | 0.160 |
Why?
|
Recombinant Fusion Proteins | 2 | 2018 | 3733 | 0.160 |
Why?
|
Thrombin | 1 | 2021 | 590 | 0.160 |
Why?
|
Coagulants | 1 | 2018 | 45 | 0.150 |
Why?
|
Bacteriophages | 1 | 2021 | 372 | 0.150 |
Why?
|
Retrospective Studies | 10 | 2021 | 80168 | 0.140 |
Why?
|
Platelet Activation | 1 | 2021 | 645 | 0.140 |
Why?
|
United States | 9 | 2023 | 72136 | 0.140 |
Why?
|
Skin Neoplasms | 1 | 2016 | 5797 | 0.140 |
Why?
|
Geography | 1 | 2019 | 660 | 0.140 |
Why?
|
Insurance Claim Review | 1 | 2021 | 737 | 0.130 |
Why?
|
Male | 17 | 2024 | 358747 | 0.130 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2018 | 280 | 0.130 |
Why?
|
Microvessels | 1 | 2019 | 572 | 0.130 |
Why?
|
Bacteremia | 1 | 2021 | 980 | 0.120 |
Why?
|
Hospitals, Pediatric | 2 | 2022 | 1854 | 0.120 |
Why?
|
Drug Administration Schedule | 1 | 2021 | 4839 | 0.110 |
Why?
|
Developmental Disabilities | 1 | 2019 | 1504 | 0.090 |
Why?
|
Female | 12 | 2021 | 390323 | 0.090 |
Why?
|
Blood Platelets | 1 | 2021 | 2475 | 0.090 |
Why?
|
Infant, Newborn | 5 | 2022 | 26183 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1668 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2018 | 1585 | 0.080 |
Why?
|
Quality of Life | 4 | 2022 | 13285 | 0.080 |
Why?
|
Pulmonary Embolism | 1 | 2021 | 2540 | 0.080 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 12951 | 0.080 |
Why?
|
Middle Aged | 8 | 2022 | 219568 | 0.070 |
Why?
|
Child Development | 1 | 2019 | 2285 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10748 | 0.070 |
Why?
|
Swine | 1 | 2017 | 5892 | 0.070 |
Why?
|
Boston | 2 | 2022 | 9304 | 0.070 |
Why?
|
Prognosis | 2 | 2020 | 29557 | 0.070 |
Why?
|
Risk Assessment | 3 | 2024 | 23884 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39059 | 0.060 |
Why?
|
Transplantation, Homologous | 1 | 2013 | 4809 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8175 | 0.060 |
Why?
|
Lung | 1 | 2022 | 9985 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14490 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18358 | 0.050 |
Why?
|
Models, Biological | 1 | 2018 | 9460 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8530 | 0.050 |
Why?
|
Inflammation | 1 | 2020 | 10718 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10652 | 0.040 |
Why?
|
Aged | 4 | 2020 | 168218 | 0.040 |
Why?
|
Survival Rate | 1 | 2013 | 12721 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2012 | 3586 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 851 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2019 | 270 | 0.040 |
Why?
|
Goals | 1 | 2024 | 707 | 0.040 |
Why?
|
Risk Factors | 4 | 2023 | 73809 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 418 | 0.040 |
Why?
|
Plasma | 1 | 2020 | 584 | 0.030 |
Why?
|
Homozygote | 1 | 2021 | 1788 | 0.030 |
Why?
|
Capillary Permeability | 1 | 2020 | 769 | 0.030 |
Why?
|
Protein Stability | 1 | 2018 | 566 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2019 | 859 | 0.030 |
Why?
|
Executive Function | 1 | 2024 | 1374 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2013 | 5649 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2019 | 1203 | 0.030 |
Why?
|
Hepatocytes | 1 | 2021 | 1230 | 0.030 |
Why?
|
Mice, SCID | 1 | 2019 | 2626 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2019 | 58683 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 54137 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2022 | 22029 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2024 | 2629 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3563 | 0.030 |
Why?
|
Embryonic Stem Cells | 1 | 2019 | 1262 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2021 | 2144 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2021 | 2297 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2018 | 960 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2020 | 2322 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 25956 | 0.020 |
Why?
|
Psychomotor Performance | 1 | 2019 | 1878 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2019 | 1599 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2024 | 7021 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2018 | 2432 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3887 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2703 | 0.020 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2024 | 3701 | 0.020 |
Why?
|
Animals | 2 | 2019 | 167768 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 41256 | 0.020 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2019 | 1842 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2018 | 2215 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3561 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2020 | 4429 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12945 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7583 | 0.020 |
Why?
|
Cognition | 1 | 2024 | 6953 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 36284 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2022 | 64378 | 0.010 |
Why?
|
Databases, Factual | 1 | 2020 | 7980 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2022 | 15785 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7403 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 12876 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 21272 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16534 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7378 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18119 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29915 | 0.010 |
Why?
|
Mice | 1 | 2019 | 81101 | 0.010 |
Why?
|